Israeli-Canadian start-up SaNOtize set up a booth at February’s OurCrowd Global Summit to test its antiviral spray, enovid. The company’s co-founder and chief science officer, Chris Miller, told me this was “the world’s first double-blind clinical trial launched at a convention.”
